Diagnostics in cancer drug development

Expert Review of Molecular Diagnostics

Volumn 4, Issue 2, 2004, Pages 127-129

  Sikora, Karol ^a,b  

^a Medical Solutions plc   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

APOPTOSIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER THERAPY; CLINICAL RESEARCH; DIAGNOSTIC IMAGING; DISEASE MARKER; DRUG RESEARCH; DRUG TARGETING; EDITORIAL; HEALTH CARE DELIVERY; HIGH RISK POPULATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; MAXIMUM TOLERATED DOSE; MITOSIS; PATIENT SELECTION; PHARMACODYNAMICS; PROGNOSIS;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG DESIGN; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; SOFTWARE;

EID: 1542328193     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.4.2.127     Document Type: Editorial

References (6)

1. Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
2. Workman P, Clarke P. Innovative cancer drug targets: genomics, transcriptomics and clinomics. Expert Opin. Pharmacother. 2, 911-915 (2001).
3. Wang SC, Zhang L, Hortobagyi GN, Hung MC. Targeting HER2: recent developments and future directions for breast cancer patients. Semin. Oncol. 28(6 Suppl. 18), 21-29 (2001).
4. Scherf U, Ross D, Waltham M et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236-244 (2000).
5. Pucci B, Kasten M, Giordano A. Cell cycle and apoptosis. Neoplasia 2, 291-299 (2000)
6. Anderson H, Price P, Blomley S et al. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br. J. Cancer 85, 1085-1093 (2001).